Review of Therapeutic Agents for Treatment of COVID-۱۹

In late December ۲۰۱۹, a cluster of unexplained pneumonia cases has been reported in Wuhan, China, named coronavirus disease ۲۰۱۹ (COVID -۱۹) which has been spreading in ۲۰۴ countries. To date no pharmaceutical products have been approved for the treatment of this viral pneumonia. Based on rapid spread of the disease and high disease burden, several agents have been proposed for treatment of this viral pneumonia, mainly antivirals and immunomodulator agents and underwent in-vitro, animal and clinical trials. Some of these agents have been revealed promising preclinical results but, non of them approved yet. This review aims to summarize the current knowledge about the mechanism and considerations of widely used investigational agents that are used in the treatment of COVID-۱۹ as off-label.

Keywords:

COVID-۱۹ , Pneumonia , Antiviral , Immunomodulator , Interferon , IVIG , Tocilizumab , Remdesivir